Delaware
(State
or Other Jurisdiction
of
Incorporation)
|
000-30929
(Commission
File Number)
|
13-4087132
(IRS
Employer Identification No.)
|
£ |
Written
communications pursuant to Rule 425 under the Securities
Act.
|
£
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange
Act.
|
£
|
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange
Act.
|
£
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act.
|
Item 5.02. |
Departure
of Directors or Principal Officers; Election of Directors; Appointment
of
Certain Officers; Compensatory Arrangements of Certain Officers.
|
(e)
|
On
February 9, 2007, the Compensation Committee of the Board of Directors
of
Keryx Biopharmaceuticals, Inc. (the “Compensation Committee”) approved
annual base salaries for fiscal year 2007 for its named executive
officers, as set forth in the following table:
|
Executive
officer
|
Base
salary
for 2007 |
||||||
Michael
S. Weiss, Chairman and Chief Executive Officer
|
$
|
390,000
|
|||||
I.
Craig Henderson, President
|
$
|
315,000
|
|||||
Ronald
C. Renaud, Jr., Senior Vice President, Chief Financial Officer, Secretary
and Treasurer
|
$
|
286,000
|
Keryx Biopharmaceuticals, Inc. | ||
(Registrant) | ||
|
|
|
Date: February 12, 2007 | By: | /s/ Ronald C. Renaud, Jr. |
Ronald C. Renaud, Jr. |
||
Senior
Vice President, Chief Financial Officer, Secretary and
Treasurer
|